Centre for Mental Health, University Health Network, Toronto, ON, Canada.
Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
CNS Drugs. 2018 Jan;32(1):65-74. doi: 10.1007/s40263-018-0490-z.
Fatigue is a frequently reported symptom in major depressive disorder, occurring in over 90% of patients. Clinical presentations of fatigue within major depressive disorder encompass overlapping physical, cognitive and emotional aspects. While this review addresses the epidemiology, burden, functional impact and management of fatigue in major depressive disorder, the main focus is on available pharmacotherapy options and their comparative efficacies. Our review of the effects of pharmacological treatments on fatigue in major depressive disorder found that medications with dopaminergic and/or noradrenergic action such as modafinil, flupenthixol and atomoxetine were most effective in improving symptoms of fatigue and low energy. However, significant variation across studies in assessment tools and study inclusion/exclusion criteria may have contributed to inconsistent findings. The efficacy of non-pharmacological interventions is also discussed, including light therapy and exercise.
疲劳是重性抑郁障碍中一种常见的报告症状,超过 90%的患者有此症状。在重性抑郁障碍中,疲劳的临床表现包括重叠的躯体、认知和情感方面。虽然本综述涉及重性抑郁障碍中疲劳的流行病学、负担、功能影响和管理,但主要重点是现有的药物治疗选择及其比较疗效。我们对药物治疗对重性抑郁障碍中疲劳的影响的综述发现,具有多巴胺能和/或去甲肾上腺素能作用的药物,如莫达非尼、氟哌噻吨和托莫西汀,在改善疲劳和低能量症状方面最有效。然而,在评估工具和研究纳入/排除标准方面,研究之间存在显著差异,这可能导致研究结果不一致。非药物干预的疗效也在讨论中,包括光疗和运动。